Jefferies Upgrades Azelis and IMCD: A Positive Shift
Jefferies analysts have made a notable upgrade for both Azelis (EBR: AZE) and IMCD (AS: IMCD), two prominent players in the specialty chemicals distribution industry, raising their ratings to 'buy'. This upgrade is based on expectations of improved market conditions that could lead to a recovery in organic revenue growth and operational efficiency starting in the latter half of 2024.
Key Drivers Behind the Upgrade
Jefferies has identified several key factors that contribute to this optimistic outlook. A significant element is the recent appointment of new CEOs at both companies, who are anticipated to introduce innovative strategic directions. Additionally, favorable changes in market conditions and the potential for advantageous mergers and acquisitions further bolster this positive forecast.
Market Dynamics and Company Strategies
Recent trends in the specialty chemicals sector suggest a potential rebound. Analysts have observed a slight increase in upstream product spreads, moving away from two-decade lows during the typically slow month of August. Azelis has reported early signs of recovery, indicating that the market's decline is beginning to stabilize, which could lead to organic growth resuming in the latter half of 2024.
Conversely, IMCD has taken a more cautious approach, reflecting some uncertainty due to inconsistent performance. However, the company acknowledges that less challenging comparisons in the future may improve its performance outlook.
The Role of Leadership in Strategic Growth
Jefferies credits part of this upgrade to anticipated strategic initiatives from the new CEOs of both Azelis and IMCD. For example, Azelis' new CEO, Anna Bertona, is set to unveil a refreshed company strategy in Istanbul, while IMCD's Valerie Diele-Braun will share her vision in Milan. These developments could strengthen their positions in formulation expertise, leveraging their asset-light and resilient business models.
Industry Trends Favoring Larger Distributors
This upgrade aligns with a broader trend of increasing outsourcing, which benefits larger distributors like Azelis and IMCD. Suppliers are increasingly opting for distributors that possess strong technical and digital capabilities, such as formulation labs and advanced customer interaction technologies. This trend poses challenges for smaller competitors, creating a favorable environment for mergers and acquisitions as smaller players struggle to compete.
Growth Strategies Focused on Mergers and Acquisitions
Both companies have been actively pursuing add-on acquisitions. Azelis, for instance, has completed 52 acquisitions over the past 7.5 years, valued at around €2.2 billion, which has generated revenues of approximately €1.8 billion. This strategy has allowed the company to achieve an incremental Return on Invested Capital (ROIC) of 11.3%.
Similarly, IMCD has carried out 61 acquisitions totaling about €1.6 billion, leading to corresponding revenues and an even higher incremental ROIC of 12.4%. Jefferies believes both companies are well-positioned to take advantage of ongoing consolidation opportunities in the specialty chemicals sector.
Financial Forecasts and Future Expectations
Following their analysis, Jefferies has updated its financial projections for Azelis and IMCD, anticipating strong organic revenue growth and improved operational capabilities. Analysts forecast a modest 2% increase in FY24E EBITA for Azelis, with expectations of a 4% recovery in the latter half of 2024, supported by a similar rise in organic revenue.
For IMCD, a 10% recovery is expected in the second half of FY24, along with a 2% organic revenue increase. As a result, this leads to a projected 2% rise in FY24E EBITA for IMCD as well.
Valuation Insights and Market Responses
Despite these positive prospects, Jefferies has pointed out a valuation disparity between the two companies. Since the start of the year, Azelis' shares have dropped by 14%, while IMCD's shares have decreased by 6%. In contrast, the EuroStoxx index has risen by 10%, highlighting a concerning gap.
Current estimates suggest that Azelis is trading at 11.9x FY25E EV/EBITA, which represents a 30% discount compared to IMCD. This difference can be partly attributed to the recent sale of an 11% stake by Azelis' 36% private equity owner, EQT, at a significant discount to market prices.
In light of these evaluations, Jefferies has raised its price target for Azelis by 26% to €24.00, reflecting improved EBITA estimates and adjustments for share overhang. For IMCD, the price target has been increased by 21% to €170.00, reflecting the enhanced EBITA figures and market premiums.
Frequently Asked Questions
What are the main factors for the upgrade of Azelis and IMCD?
The upgrade is primarily due to anticipated better market conditions, new leadership strategies, and potential for value-enhancing mergers and acquisitions.
How have the new CEOs influenced the outlook?
The new CEOs are expected to bring fresh strategies that could strengthen their companies' market positions and adapt to industry dynamics.
What growth strategies are Azelis and IMCD employing?
Both companies are aggressively pursuing mergers and acquisitions to enhance their market presence and operational capabilities.
What is the projected recovery in financial performance for these companies?
Analysts expect a rebound in organic revenue growth, with Azelis targeting a 4% recovery in the latter half of 2024 and IMCD forecasting a 10% recovery in the same period.
What is the current market perception of Azelis compared to IMCD?
Azelis is currently trading at a lower valuation than IMCD, which has raised concerns about the valuation gap despite similar growth strategies.
